公开(公告)号：US20230310600A1

公开(公告)日：2023-10-05

申请号：US18020140

申请日：2021-08-09

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Zonghai LI ,  Zhaohui LIAO

IPC: A61K39/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C07K16/28 ,  A61P35/00 ,  A61P37/06

CPC classification number: A61K39/4611 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/2809 ,  A61K39/4631 ,  A61P35/00 ,  A61P37/06 ,  C12N2310/20

Abstract: Provided are a method for engineering T-cells or pluripotent stem cells, as well as engineered T-cells and pluripotent stem cells. The method specifically comprises: engineering the T cells or pluripotent stem cells to obtain engineered T cell or engineered pluripotent stem cells with reduced expression, activity, and/or signaling of NKG2A. The obtained engineered T cell and a composition containing the engineered T cell can be used to treat diseases, such as cancer (tumor) and autoimmune diseases.

公开(公告)号：US12178786B2

公开(公告)日：2024-12-31

申请号：US16966789

申请日：2019-02-02

Applicant: CRAGE medical Co., Limited

Inventor： Zonghai Li ,  Xiuqi Wu

IPC: A61P35/00 ,  A61K31/4402 ,  A61K38/17 ,  A61K39/00 ,  C07K16/28

Abstract: Provided in the present invention is a method for treating tumor. An immune effector cell and a second treatment agent are applied to individual suffering from tumor, wherein the immune effector cell expresses a receptor for recognizing tumor antigen, and wherein the second treatment agent is a compound of formula I or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12168061B2

公开(公告)日：2024-12-17

申请号：US15750271

申请日：2016-08-02

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Huamao Wang ,  Bo Song

IPC: C07K16/30 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  G01N33/574

Abstract: The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.

公开(公告)号：US20240131065A1

公开(公告)日：2024-04-25

申请号：US18278495

申请日：2022-02-25

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Zonghai LI ,  Zhimin SHI

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N9/22

CPC classification number: A61K35/17 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/2851 ,  C12N9/22 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/55 ,  C07K2317/622 ,  C12N2310/20

Abstract: An engineered immune cell for immunotherapy, which has a relatively high persistence and/or survival rate of transplantation in a host organism, and a preparation method therefor.

公开(公告)号：US11596653B2

公开(公告)日：2023-03-07

申请号：US16164995

申请日：2018-10-19

Applicant: CRAGE medical Co., Limited

Inventor： Zonghai Li ,  Huiping Gao ,  Peng Wang ,  Hua Jiang ,  Huamao Wang

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  A61K48/00 ,  C07K16/30 ,  C07K14/725 ,  A61K9/00 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/20

Abstract: Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US11419895B2

公开(公告)日：2022-08-23

申请号：US16618047

申请日：2018-05-30

Applicant: CRAGE medical Co., Limited

Inventor： Zonghai Li ,  Peng Wang ,  Hua Jiang

IPC: C07K16/30 ,  A61K35/17 ,  A61P35/00 ,  A61K38/20 ,  C07K14/725 ,  C07K16/28

Abstract: Disclosed herein are methods of treating a subject exhibiting a cell that expresses Wilms tumor protein 1 (WT1). The methods typically utilize anti-WT1 antigen binding units or chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US20240269175A1

公开(公告)日：2024-08-15

申请号：US18174565

申请日：2023-02-24

Applicant: CRAGE medical Co., Limited

Inventor： Zonghai LI ,  Huiping GAO ,  Peng WANG ,  Hua JIANG ,  Huamao WANG

IPC: A61K35/17 ,  A61K9/00 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/20 ,  A61K48/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC classification number: A61K35/17 ,  A61K9/0019 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/2013 ,  A61K38/202 ,  A61K38/204 ,  A61K38/2073 ,  A61K48/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/303 ,  A01K2207/12 ,  A01K2227/105 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2740/16043

Abstract: Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US20230148586A1

公开(公告)日：2023-05-18

申请号：US17920515

申请日：2021-04-21

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Zonghai LI ,  Huamao WANG ,  Huiping GAO

IPC: A01N1/02 ,  C12N5/078

CPC classification number: A01N1/0221 ,  C12N5/0634 ,  C12N2500/62 ,  C12N2500/84

Abstract: The present application relates to the field of cell biology. The present application provides a cryopreservation medium for cryogenic storage of a biological sample, particularly a cryopreservation medium for cryogenic storage of cells in an apheresis sample.

公开(公告)号：US20220325241A1

公开(公告)日：2022-10-13

申请号：US17634050

申请日：2020-08-10

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Zonghai LI ,  Ruixin SUN

IPC: C12N5/0783 ,  C07K14/725 ,  C07K14/715 ,  C07K16/24 ,  C12N15/62 ,  C12N15/85

Abstract: Provided are an immune effector cell for co-expressing a chemokine receptor, a pharmaceutical composition, a kit, and a method for treating a tumor. The immune effector cell comprises a receptor that specifically recognizes claudin 18.2 and a protein that recognizes SDF-1. Further provided are an expression construct, an expression vector, and a virus. The expression construct comprises an expression of a receptor that binds to a tumor-associated antigen and an expression of the protein that recognizes SDF-1, which are connected in sequence.

公开(公告)号：US11453860B2

公开(公告)日：2022-09-27

申请号：US15532965

申请日：2015-11-30

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Huamao Wang ,  Xiumei Cai ,  Hongxia Zhao ,  Bo Song ,  Yuanmei Chen ,  Yinyu Zhu

IPC: C12N5/0783 ,  C12N5/10 ,  A61K39/395 ,  C12N15/63 ,  C07K14/00 ,  C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  C12N15/86 ,  A61K39/00

Abstract: Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.